Literature DB >> 10545713

Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?

A Lonardo1.   

Abstract

BACKGROUND: Fatty liver (FL) is the most common liver disease but its clinical significance remains elusive. Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a cause of liver failure, sometimes recurring following transplantation. Recent data on both conditions are critically reviewed.
METHODS: A Medline search of the medical literature (1990 to September 1998) and cross-references was performed.
RESULTS: FL most commonly affects middle-aged men with obesity, altered glucose metabolism, hyperlipidemia, and hypertension. The link between biology of HCV, iron metabolism and FL should be addressed. Prospective studies should also quantify the rate and the factors involved in the progression of FL to NASH. The clinical spectrum of NASH is currently broader than it was initially recognized. Diagnosis of FL and NASH may involve ultrasonography, liver biopsy, and recognition of related conditions. Treatment of these conditions must be tailored according to patient's features.
CONCLUSIONS: The clinical significance of FL is incompletely understood at present. The relationship, if any, of FL and the metabolic syndrome should be carefully investigated.

Entities:  

Mesh:

Year:  1999        PMID: 10545713     DOI: 10.1159/000016909

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  13 in total

1.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

2.  Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation.

Authors:  Osamah Hussein; Sergio Szvalb; L M Van den Akker-Berman; Nimer Assy
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.199

3.  Biochemical and histological liver changes occurred after iron supplementation and possible remediation by garlic consumption.

Authors:  Héla Ghorbel; Ines Feki; Ines Friha; Abdel Majid Khabir; Tahya Boudawara; Mohamed Boudawara; Sami Sayadi
Journal:  Endocrine       Date:  2011-05-08       Impact factor: 3.633

Review 4.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

5.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 6.  Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.

Authors:  F Lirussi; E Mastropasqua; S Orando; R Orlando
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

7.  Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  M S Mirza
Journal:  ISRN Gastroenterol       Date:  2011-08-28

8.  Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults.

Authors:  Mark M Haenle; Stefan O Brockmann; Martina Kron; Ursula Bertling; Richard A Mason; Gerald Steinbach; Bernhard O Boehm; Wolfgang Koenig; Peter Kern; Isolde Piechotowski; Wolfgang Kratzer
Journal:  BMC Public Health       Date:  2006-09-18       Impact factor: 3.295

Review 9.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

10.  Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis.

Authors:  Qian Wang; Jianjun Du; Pengfei Yu; Bin Bai; Zhanwei Zhao; Shiqi Wang; Junjie Zhu; Quanxin Feng; Yun Gao; Qingchuan Zhao; Chaoxu Liu
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.